Martin G E, Williams M, Pettibone D J, Zrada M M, Lotti V J, Taylor D A, Jones J H
J Pharmacol Exp Ther. 1985 May;233(2):395-401.
The intrinsic activity of the potent dopamine (DA) agonist 4-propyl-9-hydroxynaphthoxazine [(+)-PHNO] was examined in receptor binding assays for the following receptors: DA, alpha-1 and alpha-2 adrenergic, serotonin-1 and -2, neuroleptic, beta adrenergic, anxiolytic, adenosine A-1, gamma-aminobutyric acid, muscarinic and opiate. (+)-PHNO exhibited strong to moderate potencies [IC50 (nanomolars) in parentheses] in binding to DA (24), "neuroleptic" (67), alpha-2 adrenergic (77) and serotonin-1 (277) sites. The pharmacological activity of the naphthoxazine both in vivo and in vitro was contrasted with the known DA agonists apomorphine, pergolide, lisuride and 6-ethyl-9-oxaergoline in tests of DA, alpha-2 adrenergic and serotonergic function. Each compound was examined in vitro in receptor binding assays for interactions with DA, alpha-2 adrenergic, serotonin-1 and serotonin-2 receptors and for alpha-2 adrenergic activity in inhibiting field-stimulated contractions of the vas deferens of the rat. In vivo, alpha-2 adrenergic activity was assayed via measurement of mydriasis after i.v. injections in the rat, whereas serotonin activity was assayed by measuring drug-induced inhibition of 5-hydroxytryptophan accumulation, and DA activity was assessed by quantifying stereotyped behavior after both i.p. and i.v. injections. Selectivity ratios for the DA receptor were derived from effective dose values determined in these tests and demonstrated that only apomorphine was more selective as a DA agonist than (+)-PHNO in vivo. (+)-PHNO was the least active agent at the alpha-2 receptors in the vas deferens and with serotonergic mechanisms in vivo to reduce 5-hydroxytryptophan accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)
在针对以下受体的受体结合试验中,研究了强效多巴胺(DA)激动剂4-丙基-9-羟基萘并恶嗪[(+)-PHNO]的内在活性:DA、α-1和α-2肾上腺素能、5-羟色胺-1和-2、抗精神病药、β肾上腺素能、抗焦虑、腺苷A-1、γ-氨基丁酸、毒蕈碱和阿片受体。(+)-PHNO在与DA(24)、“抗精神病药”(67)、α-2肾上腺素能(77)和5-羟色胺-1(277)位点结合时表现出强至中等的效力[括号内为IC50(纳摩尔)]。在DA、α-2肾上腺素能和5-羟色胺能功能测试中,将萘并恶嗪的体内和体外药理活性与已知的DA激动剂阿扑吗啡、培高利特、利苏瑞和6-乙基-9-氧麦角林进行了对比。每种化合物都在体外进行了受体结合试验,以研究其与DA、α-2肾上腺素能、5-羟色胺-1和5-羟色胺-2受体的相互作用,以及在抑制大鼠输精管场刺激收缩中的α-2肾上腺素能活性。在体内,通过测量大鼠静脉注射后的散瞳情况来测定α-2肾上腺素能活性,而通过测量药物诱导的5-羟色氨酸积累抑制来测定5-羟色胺活性,并通过定量腹腔注射和静脉注射后的刻板行为来评估DA活性。DA受体的选择性比率来自于这些试验中确定的有效剂量值,结果表明,在体内只有阿扑吗啡作为DA激动剂比(+)-PHNO更具选择性。(+)-PHNO在输精管中的α-2受体以及在体内通过5-羟色胺能机制减少5-羟色氨酸积累方面活性最低。(摘要截短于250字)